Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Real-World Outcomes of Patients With HR-Positive HER2-Negative Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i in the United States

NCT06975371 is registered in ClinicalTrials.gov with Daiichi Sankyo as lead sponsor.

NCT NCT06975371
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06975371 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Real-World Outcomes of Patients With HR-Positive HER2-Negative Metastatic Breast Cancer After Treatment With First-Line ET+CDK4/6i in the United States
Lead sponsor
Daiichi Sankyo
Phase
Observational
Overall status
Completed
Start date
April 14, 2025
Completion date
August 5, 2025
Enrollment
1,415 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced/metastatic her2-negative breast cancer